See what CanVECTOR members are publishing to advance the field of venous thromboembolism
Publications since 2016 that are linked to venous thromboembolism and/or anticoagulant therapy
Publications for Jeffrey Weitz
Updated daily
Loading publication list...
| # | PubMedId | Deleted | Publication |
|---|---|---|---|
| 1 | 40653090 | 0 | Yin R, Fredenburgh JC, Weitz JI. EFFECTS OF MILVEXIAN ALONE OR WITH HEPARIN ON CATHETER-INDUCED CLOTTING AND THROMBIN GENERATION. J Thromb Haemost. 2025 Jul 11:S1538-7836(25)00417-9. doi: 10.1016/j.jtha.2025.06.028. |
| 2 | 40546068 | 0 | Al Said S, Patel SM, Giugliano RP, et al. Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial. Circulation. 2025 Jun 23. doi: 10.1161/CIRCULATIONAHA.125.074037. |
| 3 | 40499984 | 0 | Patel SM, Giugliano RP, Morrow DA, et al. Long-Acting Factor XI Inhibition and Periprocedural Bleeding: An Analysis From AZALEA-TIMI 71. J Am Coll Cardiol. 2025 Jun 17;85(23):2288-2298. doi: 10.1016/j.jacc.2025.04.018. |
| 4 | 40164778 | 0 | Capodanno D, Alexander JH, Bahit MC, et al. Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism. Nat Rev Cardiol. 2025 Mar 31. doi: 10.1038/s41569-025-01144-z. |
| 5 | 40049418 | 0 | Lanting VR, van Bergen En Henegouwen K, Bosch FTM, et al. Treatment and outcomes after on-treatment recurrent venous thromboembolism in patients with cancer: a post-hoc analysis of the Hokusai VTE Cancer study. J Thromb Haemost. 2025 Mar 4:S1538-7836(25)00120-5. doi: 10.1016/j.jtha.2025.02.022. |
| 6 | 39986336 | 0 | Gibson CM, Bahit MC, Mehran R, et al. Oral Factor XIa Inhibitor Milvexian After a Recent Acute Coronary Syndrome: Rationale and Design of the Phase 3 (Librexia ACS). Am Heart J. 2025 Feb 20:S0002-8703(25)00044-4. doi: 10.1016/j.ahj.2025.02.011. |
| 7 | 39842513 | 0 | Fredenburgh JC, Weitz JI. Exosite crosstalk in thrombin. J Thromb Haemost. 2025 Apr;23(4):1160-1168. doi: 10.1016/j.jtha.2025.01.003. Epub 2025 Jan 20. |
| 8 | 39842011 | 0 | Ruff CT, Patel SM, Giugliano RP, et al. Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation. N Engl J Med. 2025 Jan 23;392(4):361-371. doi: 10.1056/NEJMoa2406674. |
| 9 | 39283934 | 0 | Weitz JI. Arterial Thrombosis: Present and Future. Circulation. 2024 Sep 17;150(12):905-907. doi: 10.1161/CIRCULATIONAHA.124.070541. Epub 2024 Sep 16. |
| 10 | 39214801 | 0 | Jain SS, Mahaffey KW, Pieper KS, et al. Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design. Am Heart J. 2024 Aug 27:S0002-8703(24)00206-0. doi: 10.1016/j.ahj.2024.08.011. |
, McMaster University